Neisseria meningitidis: Treatment and Chemoprophylaxis
For confirmed invasive meningococcal disease, treat immediately with third-generation cephalosporins (ceftriaxone or cefotaxime), and provide chemoprophylaxis to all close contacts within 24 hours using ceftriaxone, rifampin, or ciprofloxacin—though ciprofloxacin should be avoided in areas with documented resistance. 1
Treatment of Invasive Meningococcal Disease
Third-generation cephalosporins are the reference antibiotics for confirmed or strongly suspected invasive meningococcal infections 2. These agents have the critical advantage of eradicating nasopharyngeal carriage of meningococcus, which means patients treated with intravenous ceftriaxone do not require additional prophylaxis before discharge 1. In contrast, patients treated with penicillin alone must receive clearance-effective antibiotics before leaving the hospital 1.
Chemoprophylaxis for Close Contacts
Who Requires Prophylaxis
- Household members
- Child-care center contacts
- Anyone directly exposed to the patient's oral secretions (kissing, mouth-to-mouth resuscitation, endotracheal intubation)
- Healthcare personnel managing airways or exposed to respiratory secretions
- Airplane passengers seated directly next to an index patient on flights ≥8 hours
The attack rate for household contacts is 500-800 times higher than the general population, making prophylaxis critical 3.
Timing is Critical
Administer chemoprophylaxis as soon as possible, ideally within 24 hours of identifying the index patient 3, 1. Prophylaxis given >14 days after exposure provides limited or no benefit 3. Do not delay for oropharyngeal cultures—they are not helpful and unnecessarily postpone treatment 3.
Recommended Chemoprophylaxis Regimens
Ceftriaxone (preferred during pregnancy) 3, 1:
- Children <15 years: 125 mg IM single dose
- Adults ≥15 years: 250 mg IM single dose
- Infants <1 month: 5 mg/kg every 12 hours × 2 days
- Children 1 month to 12 years: 10 mg/kg every 12 hours × 2 days (max 600 mg)
- Adults: 600 mg every 12 hours × 2 days
- Adults: 500 mg oral single dose
Critical Caveats and Emerging Resistance
Important contraindications:
- Rifampin is teratogenic and contraindicated in pregnancy; it also reduces oral contraceptive efficacy 3
- Ciprofloxacin is not recommended for children <18 years, pregnant women, or lactating women due to cartilage toxicity concerns 3
Emerging ciprofloxacin resistance is changing practice: Since 2019, ciprofloxacin-resistant N. meningitidis strains have increased in the United States 4. Health departments should avoid ciprofloxacin prophylaxis when both criteria are met in a 12-month period: ≥2 cases of ciprofloxacin-resistant disease AND ≥20% of all cases are ciprofloxacin-resistant 4. Recent reports from Spain document dual penicillin- and ciprofloxacin-resistant strains (ST-3587 harboring blaROB-1 and gyrA mutations), emphasizing the need for ongoing surveillance 5, 6.
When NOT to Give Prophylaxis
Do not provide chemoprophylaxis for:
- Contacts of patients with N. meningitidis isolated only from nonsterile sites (oropharyngeal swabs, endotracheal secretions, conjunctival swabs) 3
- Asymptomatic nasopharyngeal carriers 3
- Healthcare workers without direct respiratory secretion exposure 3
The evidence strongly supports that secondary cases after exposure to noninvasive pneumonia or conjunctivitis are rare with no substantive excess risk 3.